{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:12:00Z","timestamp":1793398320033,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40122-024-00652-z","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:13:19Z","timestamp":1726755199000},"page":"1589-1615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Patients\u2019 Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)"],"prefix":"10.1007","volume":"13","author":[{"given":"Elizabeth","family":"Seng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Lenderking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Karn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Ossipov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"652_CR1","unstructured":"International Headache Society. IHS Classification ICHD-3: Migraine. 2021. https:\/\/ichd-3.org\/1-migraine\/. Accessed Apr 2022."},{"issue":"1","key":"652_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against H. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"issue":"9","key":"652_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML, et al. Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408\u201326. https:\/\/doi.org\/10.1111\/head.13407.","journal-title":"Headache"},{"issue":"17","key":"652_CR4","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337\u201345. https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d20.","journal-title":"Neurology"},{"issue":"5","key":"652_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/head.12774","volume":"56","author":"DW Dodick","year":"2016","unstructured":"Dodick DW, Loder EW, Manack Adams A, Buse DC, Fanning KM, Reed ML, Lipton RB. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2016;56(5):821\u201334. https:\/\/doi.org\/10.1111\/head.12774.","journal-title":"Headache"},{"issue":"8","key":"652_CR6","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.12154","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(8):1300\u201311. https:\/\/doi.org\/10.1111\/head.12154.","journal-title":"Headache"},{"issue":"2","key":"652_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Nicholson RA, Reed ML, Araujo Andre B, Jaffe DH, Faries DE, et al. Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. Headache J Head Face Pain. 2022;62(2):122\u201340. https:\/\/doi.org\/10.1111\/head.14259.","journal-title":"Headache J Head Face Pain"},{"issue":"Suppl 1","key":"652_CR8","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1097\/j.pain.0000000000001981","volume":"161","author":"U Bingel","year":"2020","unstructured":"Bingel U. Placebo 2.0: the impact of expectations on analgesic treatment outcome. Pain. 2020;161(Suppl 1):S48\u201356. https:\/\/doi.org\/10.1097\/j.pain.0000000000001981.","journal-title":"Pain"},{"key":"652_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fpsyg.2017.00233","volume":"8","author":"JA Laferton","year":"2017","unstructured":"Laferton JA, Kube T, Salzmann S, Auer CJ, Shedden-Mora MC. Patients\u2019 expectations regarding medical treatment: a critical review of concepts and their assessment. Front Psychol. 2017;8:233. https:\/\/doi.org\/10.3389\/fpsyg.2017.00233.","journal-title":"Front Psychol"},{"issue":"2","key":"652_CR10","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1097\/j.pain.0000000000002341","volume":"163","author":"K Schmidt","year":"2022","unstructured":"Schmidt K, Berding T, Kleine-Borgmann J, Engler H, Holle-Lee D, Gaul C, Bingel U. The beneficial effect of positive treatment expectations on pharmacological migraine prophylaxis. Pain. 2022;163(2):e319\u201327. https:\/\/doi.org\/10.1097\/j.pain.0000000000002341.","journal-title":"Pain"},{"key":"652_CR11","unstructured":"Centers for Disease Control and Prevention. National Health Interview Survey. Cited from: https:\/\/www.cdc.gov\/nchs\/nhis\/data-questionnaires-documentation.htm. 2023."},{"issue":"2","key":"652_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mcna.2012.11.002","volume":"97","author":"BM Abrams","year":"2013","unstructured":"Abrams BM. Factors that cause concern. Med Clin North Am. 2013;97(2):225\u201342. https:\/\/doi.org\/10.1016\/j.mcna.2012.11.002.","journal-title":"Med Clin North Am"},{"issue":"3","key":"652_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1586\/ern.13.24","volume":"13","author":"M Eller","year":"2013","unstructured":"Eller M, Goadsby PJ. MRI in headache. Expert Rev Neurother. 2013;13(3):263\u201373. https:\/\/doi.org\/10.1586\/ern.13.24.","journal-title":"Expert Rev Neurother"},{"key":"652_CR14","first-page":"33","volume-title":"Managing your headaches","author":"MW Green","year":"2001","unstructured":"Green MW, Green LM. Are you sure i don\u2019t have a brain tumor? In: Managing your headaches. New York, NY: Springer; 2001. p. 33\u201345."},{"issue":"3","key":"652_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208074","volume":"102","author":"RE Shapiro","year":"2024","unstructured":"Shapiro RE, Nicholson RA, Seng EK, Buse DC, Reed ML, Zagar AJ, et al. Migraine-related stigma and its relationship to disability, interictal burden, and quality of life: results of the OVERCOME (US) study. Neurology. 2024;102(3): e208074. https:\/\/doi.org\/10.1212\/WNL.0000000000208074.","journal-title":"Neurology"},{"issue":"5","key":"652_CR16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1592\/phco.24.6.638.34751","volume":"24","author":"R Wenzel","year":"2004","unstructured":"Wenzel R, Dortch M, Cady R, Lofland JH, Diamond S. Migraine headache misconceptions: barriers to effective care. Pharmacotherapy. 2004;24(5):638\u201348. https:\/\/doi.org\/10.1592\/phco.24.6.638.34751.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"652_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12(10):575\u201383. https:\/\/doi.org\/10.1038\/nrneurol.2016.124.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"652_CR18","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1016\/s0149-2918(03)80345-4","volume":"25","author":"DL Patrick","year":"2003","unstructured":"Patrick DL, Martin ML, Bushnell DM, Pesa J. Measuring satisfaction with migraine treatment: expectations, importance, outcomes, and global ratings. Clin Ther. 2003;25(11):2920\u201335. https:\/\/doi.org\/10.1016\/s0149-2918(03)80345-4.","journal-title":"Clin Ther"},{"issue":"2","key":"652_CR19","first-page":"95","volume":"25","author":"SJ Tepper","year":"2004","unstructured":"Tepper SJ. New thoughts on sinus headache. Allergy Asthma Proc. 2004;25(2):95\u20136.","journal-title":"Allergy Asthma Proc"},{"issue":"8","key":"652_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11910-021-01127-w","volume":"21","author":"J Robblee","year":"2021","unstructured":"Robblee J, Secora KA. Debunking myths: sinus headache. Curr Neurol Neurosci Rep. 2021;21(8):42. https:\/\/doi.org\/10.1007\/s11910-021-01127-w.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"652_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1526-4610.2006.00688.x","volume":"47","author":"E Eross","year":"2007","unstructured":"Eross E, Dodick D, Eross M. The Sinus, Allergy and Migraine Study (SAMS). Headache. 2007;47(2):213\u201324. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00688.x.","journal-title":"Headache"},{"issue":"2","key":"652_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.otc.2013.10.010","volume":"47","author":"RK Cady","year":"2014","unstructured":"Cady RK. Red flags and comfort signs for ominous secondary headaches. Otolaryngol Clin North Am. 2014;47(2):289\u201399. https:\/\/doi.org\/10.1016\/j.otc.2013.10.010.","journal-title":"Otolaryngol Clin North Am"},{"key":"652_CR23","first-page":"42","volume-title":"The self-regulation of health and illness behaviour","author":"H Leventhal","year":"2003","unstructured":"Leventhal H, Brissette I, Leventhal EA. The common-sense model of self-regulation of health and illness. In: The self-regulation of health and illness behaviour. New York, NY, US: Routledge; 2003. p. 42\u201365."},{"issue":"1","key":"652_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-022-01448-2","volume":"23","author":"P Irimia","year":"2022","unstructured":"Irimia P, Garc\u00eda-Azor\u00edn D, N\u00fa\u00f1ez M, D\u00edaz-Cerezo S, de Polavieja PG, Panni T, et al. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain. 2022;23(1):78. https:\/\/doi.org\/10.1186\/s10194-022-01448-2.","journal-title":"J Headache Pain"},{"issue":"1","key":"652_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-024-01725-2","volume":"25","author":"AJ Starling","year":"2024","unstructured":"Starling AJ, Cady R, Buse DC, Buzby M, Spinale C, Steinberg K, et al. Harris poll migraine report card: population-based examination of high-frequency headache\/migraine and acute medication overuse. J Headache Pain. 2024;25(1):26. https:\/\/doi.org\/10.1186\/s10194-024-01725-2.","journal-title":"J Headache Pain"},{"issue":"1","key":"652_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12883-020-01839-5","volume":"20","author":"M Delussi","year":"2020","unstructured":"Delussi M, Vecchio E, Libro G, Quitadamo S, de Tommaso M. Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center. BMC Neurol. 2020;20(1):256. https:\/\/doi.org\/10.1186\/s12883-020-01839-5.","journal-title":"BMC Neurol"},{"issue":"1","key":"652_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10194-023-01682-2","volume":"24","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Fitzek M, Overeem LH, Triller P, Siebert A, et al. Impact of a reimbursement policy change on treatment with erenumab in migraine: a real-world experience from Germany. J Headache Pain. 2023;24(1):144. https:\/\/doi.org\/10.1186\/s10194-023-01682-2.","journal-title":"J Headache Pain"},{"issue":"1","key":"652_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-024-01727-0","volume":"25","author":"C Lazaro-Hernandez","year":"2024","unstructured":"Lazaro-Hernandez C, Caronna E, Rosell-Mirmi J, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population. J Headache Pain. 2024;25(1):21. https:\/\/doi.org\/10.1186\/s10194-024-01727-0.","journal-title":"J Headache Pain"},{"issue":"1","key":"652_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-023-01637-7","volume":"24","author":"J Schoenen","year":"2023","unstructured":"Schoenen J, Van Dycke A, Versijpt J, Paemeleire K. Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review. J Headache Pain. 2023;24(1):99. https:\/\/doi.org\/10.1186\/s10194-023-01637-7.","journal-title":"J Headache Pain"},{"issue":"8","key":"652_CR30","doi-asserted-by":"publisher","first-page":"818","DOI":"10.18553\/jmcp.2022.28.8.818","volume":"28","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene\u2013related peptide inhibitors vs other preventive migraine treatments in the United States. J Manag Care Spec Pharm. 2022;28(8):818\u201329. https:\/\/doi.org\/10.18553\/jmcp.2022.28.8.818.","journal-title":"J Manag Care Spec Pharm"},{"key":"652_CR31","doi-asserted-by":"crossref","unstructured":"Varnado OJ, Vu M, Buysman E, Kim G, Allenback G, Hoyt M, et al. Healthcare resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States. Journal of Managed Care & Specialty Pharmacy (2024, in press).","DOI":"10.18553\/jmcp.2024.30.8.792"},{"issue":"4","key":"652_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/03007995.2024.2316864","volume":"40","author":"OJ Varnado","year":"2024","unstructured":"Varnado OJ, Vu M, Buysman EK, Kim G, Allenback G, Hoyt M, et al. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study. Curr Med Res Opin. 2024;40(4):635\u201346. https:\/\/doi.org\/10.1080\/03007995.2024.2316864.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"652_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain. 2022;23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"issue":"4","key":"652_CR34","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644\u201355. https:\/\/doi.org\/10.1111\/head.12055.","journal-title":"Headache"},{"issue":"5","key":"652_CR35","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470\u201385. https:\/\/doi.org\/10.1177\/0333102416678382.","journal-title":"Cephalalgia"},{"issue":"6","key":"652_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388. https:\/\/doi.org\/10.1177\/0333102414547138.","journal-title":"Cephalalgia"},{"issue":"3","key":"652_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301\u201315. https:\/\/doi.org\/10.1177\/0333102410381145.","journal-title":"Cephalalgia"},{"issue":"7","key":"652_CR38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Society tBoDotAH. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain. 2021;61(7):1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache: J Head Face Pain"},{"key":"652_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, Society TAH. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache: J Head Face Pain. 2024. https:\/\/doi.org\/10.1111\/head.14692.","journal-title":"Headache: J Head Face Pain"},{"issue":"11","key":"652_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954\u201376. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3.","journal-title":"Lancet Neurol"},{"issue":"2","key":"652_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015.","journal-title":"Physiol Rev"},{"key":"652_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.800605","volume":"12","author":"P Amiri","year":"2021","unstructured":"Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2021;12: 800605. https:\/\/doi.org\/10.3389\/fneur.2021.800605.","journal-title":"Front Neurol"},{"issue":"1","key":"652_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-023-01624-y","volume":"24","author":"M Piccininni","year":"2023","unstructured":"Piccininni M, Brinks R, Rohmann JL, Kurth T. Estimation of migraine prevalence considering active and inactive states across different age groups. J Headache Pain. 2023;24(1):83. https:\/\/doi.org\/10.1186\/s10194-023-01624-y.","journal-title":"J Headache Pain"},{"issue":"10","key":"652_CR44","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/head.14004","volume":"60","author":"C Lt","year":"2020","unstructured":"Lt C, Spears RC, Flippen C 2nd. Equity of African American Men in headache in the United States: a perspective from African American headache medicine specialists (part 1). Headache. 2020;60(10):2473\u201385. https:\/\/doi.org\/10.1111\/head.14004.","journal-title":"Headache"},{"key":"652_CR45","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1778639","author":"MA Perez","year":"2024","unstructured":"Perez MA, Reyes-Esteves S, Mendizabal A. Racial and ethnic disparities in neurological care in the United States. Semin Neurol. 2024. https:\/\/doi.org\/10.1055\/s-0043-1778639.","journal-title":"Semin Neurol"},{"issue":"2","key":"652_CR46","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/0333102418786266","volume":"39","author":"AI Scher","year":"2019","unstructured":"Scher AI, Wang SJ, Katsarava Z, Buse DC, Fanning KM, Adams AM, Lipton RB. Epidemiology of migraine in men: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Cephalalgia. 2019;39(2):296\u2013305. https:\/\/doi.org\/10.1177\/0333102418786266.","journal-title":"Cephalalgia"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00652-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-024-00652-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00652-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:12:41Z","timestamp":1730977961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-024-00652-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1007\/s40122-024-00652-z","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elizabeth Seng: research funding from the National Institutes of Health, Veterans Health Administration, Cystic Fibrosis Foundation, and the American Heart Association, as well as fees for consulting from GlaxoSmithKline, Theranica, and Abbvie. Christian Lampl: consulting fees and honoraria for lectures\/ presentations from AbbVie\/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva. Principal investigator in clinical trials as the for Eli Lilly. Past-president of the European Headache Federation and associate editor for The Journal of Headache and Pain. Lars Viktrup, Margaret Hoyt, Gilwan Kim,, and Dustin Ruff are employees of Eli Lilly and Company and may own Lilly stock. Maurice Vincent was an employee of Eli Lilly and Company when the study was performed and may own Lilly stock. William R. Lenderking, Hayley Karn, Michael H. Ossipov are employees of Evidera.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the IRB Ethical & Independent Review Services (Study # 22143-01) and conformed with International Conference on Harmonization guidelines and was conducted in accordance with the World Medical Association Declaration of Helsinki and applicable local data protection laws. All patients provided informed consent via an electronic informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}